Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis

NCT04709458 · clinicaltrials.gov ↗
PHASE1
Phase
UNKNOWN
Status
10
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Taiga Biotechnologies, Inc.